A 58-year-old male with a three-year history of controlled primary hypertension presented with moderate erectile dysfunction (ED). The diagnostic protocol utilised the International Index of Erectile Function (IIEF-5) to establish baseline clinical impairment.
Pharmacological intervention with sildenafil citrate, a selective phosphodiesterase type 5 (PDE5) inhibitor, was initiated in accordance with standard guidelines. Dose optimisation achieved optimal haemodynamic tolerance and high clinical efficacy.
The patient achieved complete restoration of erectile capacity without sustaining significant adverse drug reactions or orthostatic hypotensive crises. This evidence-based outcome validates the safety profile of sildenafil citrate in patients with comorbid vascular disease under structured monitoring.
Case Presentation
A 58-year-old male presented to the outpatient urology clinic reporting a 24-month progression of erectile dysfunction. The patient described a persistent inability to achieve and maintain penile tumescence sufficient for penetrative intercourse. This impairment caused severe psychological distress, reduced self-esteem, and notable marital discord.
His ongoing medical co-morbidity comprised primary essential hypertension, diagnosed four years previously. He maintained stable blood pressure control using an angiotensin-converting enzyme (ACE) inhibitor mono-therapy regimen. The patient reported no history of diabetes mellitus, peripheral arterial disease, or structural cavernous abnormalities. He was a non-smoker, consumed minimal alcohol, and reported a moderate exercise routine.
Baseline physical and physiological examinations revealed a well-nourished male with a body mass index of 26.4. His resting vital signs showed a stable systolic blood pressure of 134/84 mmHg.
His resting radial heart rate was regular at 74 beats per minute. The clinician noted completely normal secondary sexual characteristics alongside unremarkable external genitalia and digital rectal assessments.
Diagnostic Assessment
The clinical investigator initiated diagnostic reasoning by evaluating the severity of the patient’s erectile dysfunction symptoms. The validated 5-item International Index of Erectile Function (IIEF-5) diagnostic questionnaire served as the primary assessment tool. The patient recorded a baseline IIEF-5 score of 11/25, consistent with moderate ED.
Laboratory screening ruled out underlying endocrinopathies, metabolic syndromic features, and advanced renal or hepatic impairment. Total serum testosterone measured 14.8 nmol/L, which falls well within the normal physiological reference range. Fasting plasma glucose registered 4.9 mmol/L, and the serum lipid profile demonstrated optimal cardiovascular control parameters.
The physician calculated a QRISK3 ten-year cardiovascular disease risk score to confirm systemic safety margins. The resulting score indicated a low-to-moderate risk profile, permitting the safe introduction of vasoactive medicines. The diagnostic evaluation concluded that the erectile impairment was primarily organic, driven by mild age-related vascular insufficiency.
Pharmacological Mechanism
Sildenafil citrate treats erectile dysfunction by functioning as a potent, highly selective inhibitor of the PDE5 enzyme. This specific isoenzyme is heavily concentrated within the smooth muscle tissues of the penile corpora cavernosa. The therapeutic mechanism relies completely on a functioning, endogenous nitric oxide (NO) chemical pathway during stimulation.
Sexual arousal triggers the release of nitric oxide from local non-adrenergic non-cholinergic nerve terminals and endothelial cells. Free nitric oxide activates the intracellular enzyme guanylyl cyclase, converting guanosine triphosphate into cyclic guanosine monophosphate. Accumulating cGMP (a molecule that relaxes smooth muscle) induces immediate intracellular calcium depletion, relaxing corporate smooth muscle walls.
Smooth muscle relaxation locally lowers systemic vascular resistance, thereby accelerating arterial inflow into the cavernous spaces. Sildenafil citrate acts by competitively blocking the catalytic site of the PDE5 degradation enzyme. By halting this breakdown, the drug preserves elevated cGMP concentrations, extending the natural erectile response.
Therapeutic Intervention
The therapeutic intervention followed a conservative, structured strategy in accordance with British National Formulary (BNF) protocols. The clinician selected sildenafil citrate as the primary vasoactive treatment owing to its predictable, well-characterised pharmacokinetics. The patient received comprehensive instructions to ingest the tablet approximately 60 minutes prior to anticipated sexual intercourse.
The medicine is manufactured in three standard licensed strengths: 25mg, 50mg, and 100mg solid oral tablets. Because the patient was concurrently taking an antihypertensive medicine, the clinician prescribed a standard 50mg initial dose. This strength allows optimal evaluation of initial efficacy while mitigating potential synergistic systemic drops in blood pressure.
View available clinical-grade formulations of sildenafil citrate here.
The clinical team carefully assessed the patient’s concurrent medication profile for potential drug-drug interactions. The patient was not taking any strong CYP3A4 inhibitors, such as erythromycin or ketoconazole. Co-administration with CYP3A4 inhibitors limits hepatic clearance, necessitating a lower initial titration step using the 25mg strength. Conversely, if initial tolerance is high but response is partial, titration up to the 100mg strength is authorised.
Clinical Data
| IIEF-5 Symptom Score | 11 / 25 (Moderate ED) | 23 / 25 (Normal Function) |
| Systolic Blood Pressure | 134 mmHg | 130 mmHg |
| Diastolic Blood Pressure | 84 mmHg | 80 mmHg |
| Resting Heart Rate | 74 bpm | 76 bpm |
| Erectile Maintenance Success | Less than 20% of attempts | Greater than 80% of attempts |
Follow-Up and Outcomes
The clinical team scheduled a comprehensive follow-up evaluation twelve weeks after initiating the sildenafil programme. The patient reported a substantial, highly satisfactory improvement in both the ability to achieve and maintain rigid penile erections. His post-treatment IIEF-5 score rose to 23 out of 25, indicating normal erectile function.
The patient successfully utilised the 50mg tablets on eight separate occasions during the twelve-week trial period. He reported a rapid, predictable onset of action, typically occurring within 45 minutes of oral administration. He denied experiencing severe systemic adverse events, severe orthostatic dizziness, or prolonged visual adjustments.
The patient noted a mild, transient episode of facial flushing after his second dose of the medicine. This effect resolved spontaneously within 90 minutes and did not cause discontinuation of the treatment programme. Follow-up haemodynamic measurements confirmed excellent systemic tolerance, with a post-treatment resting blood pressure of 130/80 mmHg.
Discussion
The therapeutic outcomes observed in this case report align tightly with established NICE guidelines and clinical pharmacokinetics. In healthy adult populations, sildenafil citrate undergoes rapid gastrointestinal absorption following oral administration under fasting conditions. The active compound exhibits a reliable time to maximum concentration ($T_{max}$), peaking within 30 to 120 minutes.
The terminal elimination half-life is approximately 3 to 5 hours, which correlates with the patient’s reported efficacy window. Because the patient maintained stable blood pressure control via ACE inhibition, no dangerous synergistic hypotensive events occurred. Titrating across licensed strengths requires clinicians to carefully balance therapeutic outcomes against personal vascular safety margins.
NICE protocols emphasise that treating secondary erectile dysfunction requires managing global cardiovascular health alongside targeted drug delivery. Lifestyle modifications, including aerodynamically sustained exercise and healthy dietary patterns, complement the clinical utility of PDE5 inhibitors. The patient committed to a walking programme to further improve long-term endothelial health.
Clinical Safety Notes
Prescribers must maintain absolute vigilance regarding the absolute contraindications associated with all PDE5 inhibitor medicines.
Co-administration of sildenafil citrate with organic nitrates or nitric oxide donors is strictly contraindicated under all circumstances. This drug combination causes powerful, synergistic cGMP accumulation, which can precipitate catastrophic, fatal systemic hypotension.
Clinicians must screen all prospective candidates for active unstable angina, recent myocardial infarction, or hereditary retinal dystrophies. Any patient experiencing a continuous, painful erection lasting over four hours (priapism) requires immediate emergency medical intervention. Healthcare professionals must report all suspected adverse drug reactions to the official MHRA Yellow Card scheme.
Conclusion
Sildenafil citrate provides safe, highly predictable clinical efficacy when managed appropriately within structured UK primary care frameworks. This case illustrates that comorbid mild hypertension does not preclude successful, authority-approved treatment for erectile dysfunction. Adhering strictly to established BNF dosing guidelines ensures high patient safety margins and maximises compliance rates. Comprehensive pre-treatment screening, coupled with patient education on timing and contraindications, optimises long-term therapeutic outcomes.
References
- Sildenafil Summary of Product Characteristics (SmPC)
- Sildenafil (Viagra) for Male Erectile Dysfunction: A Meta-Analysis (PMC)
Medical Disclaimer
This document is intended solely for educational and clinical informational purposes for healthcare practitioners. It does not constitute formal medical advice, diagnosis, or a specific endorsement of self-medication protocols.